

# Mucormycosis & pythiosis – new insights

# Dr Ariya Chindamporn

Associate Professor

Department of Microbiology

Faculty of Medicine, Chulalongkorn University

Bangkok, Thailand







Hot topics in Asian medical mycology

Mucormycosis & Pythiosis – new insight

Ariya Chindamporn

Department of Microbiology, Faculty of Medicine,
Chulalongkorn University
Bangkok, Thailand





#### Mucormycosis

# Outline

- Introduction
- Recent Taxonomy
- Trend of incidence
- Epidemiology between developed and developing countries
- Pathogenesis: role of CotH receptor agents –agents causing infection


  Treatment




#### Taxonomy of Fungi Causing Mucormycosis and Entomophthoramycosis (Zygomycosis) and Nomenclature of the Disease: Molecular Mycologic Perspectives

#### Kyung J. Kwon-Chung

Molecular Microbiology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland



**Figure 1.** Old (*A*) and a proposed new (*B*) classification schemes of the kingdom Fungi.



**Figure 3.** Phylogenetic tree provided by T. Y. James at the University of Michigan, Ann Arbor, which was based on unpublished results from the AFTOL (Assembling the Fungal Tree of Life) project [10]. Results are similar to those reported by James et al [5], but additional basal taxa are included.

# Mucormycosis **VS** Entomophthoromycosis

|                             | Mucormycosis  | Entomophthoromycosis   |
|-----------------------------|---|--|
| Synonym                     | Phycomycosis, Zygomycosis   | , 6, 20  |
| Infection<br>- Host, mostly | Immunocompromised: HM, HSCT, SOT, Diabetic ketoacidosis                                 | Immunocompetent  |
| Clin. Manifestation         | Sinus, Pulmonary, Cutaneous, GI,<br>Acute thrombosis                                    | Chronic & Subcutaneous   |
| Treatment                   | AmphotericinB, posaconazole   | Itraconazole   |
| Route of infection          | Inhalation, ingestion, or through direct inoculation via abraded skin                   | Abrasion   |
| Pathogenic form             | Aseptate hyphae 3-25 um, thin wall, non dichotomous branching                           | Aseptate hyphae surround by thick eosinophilic sleeves   |
| Habitat                     | Decaying organic substrate  | Amphibians, GI of Lizard, decayed plan   |
| Distribution                | World wide  | Tropical & Subtropical   |
| Pathogen                    | Subphylum Mucoromycotina: Order Mucorales: Rhizopus, Mucor, Lichtheimia (Absidia), etc. | Subphylum Entomophthoromycotina:<br>Order Entomophthorales: <i>Basidiobolus</i><br><i>Conidiobolus</i> |

# Subcutaneous Saksenaea vasiformis infection presenting as disfiguring facial plagues

- 51 yr –old labourer
- 2 mo. painless mass, Normal nasal cavity
   & nasopharynxgeal mucosa
- History:
  - 4 mo. before: shallow abrasion
  - Abt & debridement mass enlarged
  - No systemic symptom

AmB (1.2 mg/kg/d) & Itra (600 mg/d) 40 d.



Diffuse erythematous infil. w skin thickening over forehead, both eyelids & nose



After AmB & Itra




Fig. Diffuse granulomas in the reticular dermis & subcu. tissue w necrobiotic collagen. H&E, x200



TS1-2 region




Fig. Aseptate in multinucleated giant cells, PASx200

# Anamorph & Teleomorph Characters in Mucorales VS Entomophthorales





Figure 4. Morphology of conidia and zygospores (scale bar, 20 μm). *A*, Reproduction of a conidium in *Basidiobolus ranarum*. A conidium discharged onto a Petri dish cover germinated and produced a conidiophore bearing a single conidium. *B*, Primary conidia of *Conidiobolus incongruus* germinated to produce long hyphae bearing subglobose conidia [38]. *C*, Secondary conidium formation by replication in *Conidiobolus coronatus*. *D*, Zygospore of *Basidiobolus ranarum*, with a characteristic beak, is produced by the fusion of 2 adjacent hyphal cells. *E*, Sporangial structure of *Rhizopus* species showing the sporangiophore (*S*), apophysis (*A*), columella (*C*), and sporangiospores (*SP*). *F*, Sporangium of *Lichtheimia* (*Absidia*) *corymbifera*. *G*, Electron microscopy of Zygospore (*ZS*) of *Rhizopus* species produced between 2 suspensors (*S*) originating from hyphae of 2 sexually compatible strains (courtesy of Dr S. L. Flegler). Images in *A* and *C–F* are from Kwon-Chung and Bennett [33].

# Annual number of published articles on mucormycosis since 1975 (SCOPUS, accessed July, 2013)



# **Underlying Conditions in Mucormycosis patients in various studies**

|          |               | _            |      | Unde                              | rlying      | conditio | ns % o | f cases            |                |                         |
|----------|---------------|--------------|------|-----------------------------------|-------------|----------|--------|--------------------|----------------|-------------------------|
| Location | Period        | Cases<br>No. | DM   | НМ                                | SOM/<br>SOT | DFO      | HIV    | Autolm/<br>Cortico | Trauma<br>/ no | Ref.                    |
| Global   | 1885-<br>2004 | 929          | 36.0 | 21.0                              | 7.0         | 6.0      | 2.0    | 1.0                | 19.0           | Roden et al.<br>2005    |
| France   | 1997-<br>2006 | 53           | 16.2 | 17.3                              | 7.1         |          | 4.9    |                    | 54.4           | Bitar etal. 2009        |
| Italy    | 2004-<br>2007 | 60           | 18   | 61.7                              | 1.7         | LP CO    | 1.7    | 3.3                | 40.0           | Pagano et al.2009       |
| Belgium  | 2000-<br>2009 | 31           | 6.4  | 77.0                              | 13.0        | × ×      | 3.0    |                    | 13.0           | Saegeman et al.2010     |
| Global   | 2006-<br>2009 | 41           | 17.1 | 63.4                              | 9.8         |          |        |                    |                | Ruping et al. 2009      |
| Europe   | 2005-<br>2007 | 230(>1-8%)   | 17.0 | 55.0                              | 9.0         | 1.0      | 2.0    | 7.0                | 20.0           | Skiada et al., 2011     |
| India    | 2006-<br>2007 | 178          | 73.6 | O1.1                              | 0.6         |          |        |                    | 19.1           | Chakarbarti et al. 2006 |
| Spain    | 2007-<br>2015 | 19           | 0    | 52.6                              |             |          |        |                    | 52.6           | Guinea et al.2017       |
| Mexico   | 1982-<br>2016 | 418          | 72   | 18 <sup>(5/77DM)</sup><br>93 (HM) |             |          |        |                    | 9.3            | Corzo-Leon et al. 2017  |

Medical Mycology, 2017, Vol. 00, No. 00

**Table 1.** Demographic and clinical characteristics: differences between populations with diabetes and malignancy.

| Characteristic                 | Diabetes<br>N = 302/418 (72%) | Malignancy* [77/418 (18%) Hematological 72/77 (93%) | Total population** N = 418 (%) |
|--------------------------------|-------------------------------|---|--------------------------------|
| Age, years (median, IIR)       | 50 (38–60)                    | 26 (18–43)  | 42 (0–80)                      |
| Sex (Male)                     | 96/187 (51)                   | 11/27 (41)  | 225 (54)                       |
| Mortality rate                 | 101/192 (53)                  | 11/25 (44)  | 127/246 (52)                   |
| $N = 246  (\%)^a$              |                               | 11/23 (48)  |                                |
| Type of infection <sup>b</sup> | N = 181  (%)                  | N = 31 (%)  | N = 418  (%)                   |
| Sinus (overall)                | 159 (88)                      | 11 (3.5)  | 315 (75)                       |
| Palatine infection             | 39/159 (24)                   | 2/11 (18)   | 45/315 (14)                    |
| Sinocerebral/cerebral          | 85/159 (53)                   | 3(11 (27)   | 210/315 (66)                   |
| Pulmonary                      | 8 (4)                         | 11 (35)   | 26 (6)                         |
| Cutaneous                      | 9 (5)                         | 26  | 28 (6.5)                       |
| Disseminated <sup>+</sup>      | 2 (1)                         | 4 (13)  | 23 (5.5)                       |
| Unspecified***                 | 1 (0.5)                       | CX 0  | 19 (4.5)                       |
| Abdominal <sup>++</sup>        | 1 (0.5)                       | 3 (10)  | 5 (1)                          |
| Cerebral &                     | 1 (0.5)                       | 0   | 2 (0.5)                        |

IIR, Interquartile interval range.

<sup>&</sup>lt;sup>a</sup>Mortality rate estimated with the available information of 246 individuals.

<sup>&</sup>lt;sup>b</sup>Type of infection was estimated depending on the number of individuals with available information: 181 with diabetes mellitus and 31 with malignancy.

Although an overall estimation was possible for some variables among the 418 cases, in some reports only the site of infection was reported without mention of the underlying disease.

<sup>\*</sup> Five individuals with malignancy had diabetes mellitus as comorbidity

<sup>\*\*</sup> Includes cases without underlying condition or without diabetes and without malignancy (N = 39, 9.3%). This group had mortality rate in 52% (15/29). Ten individuals with no underlying condition (19/39, 49%) did not have information available and eight were reported as previously healthy. Prior trauma was present in eight of 39 (20%), of these five individuals had no other associated condition. Five individuals had autoimmune disease (5/39, 13%), three with HIV (human immunodeficiency virus) infection (3/39, 8%), other prior conditions were drug toxicity (2/39, 5%), post-surgery (2/39, 5%). Drug toxicities consisted in agranulocytosis or neutropenia due to drugs. Numbers reported in populations with diabetes and malignancy vary due to the availability of the information.

<sup>\*\*\*</sup> Unspecified: refers to information of the site/type of infection was unavailable

<sup>+2</sup> or more sites affected.

<sup>&</sup>lt;sup>++</sup>Only abdominal infection. These were gastric, renal, hepatic, splenic, and intestinal presentation.

<sup>&</sup>lt;sup>&</sup>Only due to trauma and postsurgical process, no sinus infection.

#### Literature review in Mexico 1982-2015

13%

15%


4%

27%

Diabetes

N=181

88%



N=31

36%

27%

N = 26

Table 6. Clinical isolates reported from 250 patients.

| Organism isolated           | Total population n = 250 (%) |
|-----------------------------|------------------------------|
| Rhizopus species            | 148 (59)                     |
| Rhizopus oryzae/R. arrhizus | 108/148 (73)                 |
| Rhizopus sp.                | 34/148 (23)                  |
| Rhizopus rhizopodiformis    | 2/148 (1.3)                  |
| Rhizopus microsporus        | 2/148 (1.3)                  |
| Rhizopus azygosporus        | 1/148 (0.6)                  |
| Rhizopus pusillus           | 1/148 (0.6)                  |
| Mucor species               | 71 (28)                      |
| Mucor sp.                   | 66/71 (93)                   |
| Mucor circinelloides        | 5/71 (7)                     |
| Rhizomucor sp.              | 10 (4)                       |
| Lichtheimia corymbifera     | 8 (3)                        |
| Cunninghamella sp.          | 4 (1.5)                      |
| Syncephalastrum racemosum   | 3 (1)                        |
| Basidiobolus sp.            | 3 (1)                        |
| Conidiobolus sp.            | 1 (0.5)                      |
| Apophysomyces mexicanus     | 1 (0.5)                      |
| Absidia sp.                 | 1 (0.5)                      |

# Performance of Diagnostic Testing

| Diag tool                  | nonspecialized<br>center | specialized<br>center | Total            |
|----------------------------|--------------------------|-----------------------|------------------|
| Pos. Direct smear/cytology | 73/76 (95%)              | 158/158 (100%)        | 231/234<br>(98%) |
| Pos. Culture               | 120/211 (57%)            | 142/158 (90%)         | 262/369<br>(71%) |

- 158/369 (41%) cases were reported by a specialized center,
- 211 cases by non specialized center

**Figure 3.** Clinical presentations of mucormycosis and entomophthoromycosis in Mexico. Pie charts showing the clinical presentations by underlying


Lung

■ Skin

Intrabdominal

Diseminated

# **Etiologic agents of Zygomycosis (Mucormycosis)**



The data shown are from studies by Chakrabarti et al., Mohapatra (India)., Skiada (Europe), Lanterniaer et al. (France), and Pagano et al. (Italy)


# **Laboratory Diagnosis**

- Collect specimens: pus, bloody tissue, debrison
- Transportation : Not on ice
- Processing :
  - Cut into small pieces in sterile plate
  - Direct examination : KOH preparation, KOH calcofluor stain REPORT
  - Other common stain in Microbiot lab. Gram stain, AFB stain REPORT
  - Histopathology: tissue reaction (H&E, PAS); shape (GMS)
  - Culture: SDA, SDA+abt, SDB, Blood agar 2-3 days, 30&35C
  - Identification: classical (colony & sporulation)/ PCR/ MALDI-TOF
- Serology : Negative GM & BG

# **Pathogenesis of Mucormycosis**

#### **Sizes**

- 3-11um
- >10 um



- IR: Steriod: impair of migration, ingestion. Phagolysosome fusion
- Hemat. Malignacies: Neutropenia: impair chemotaxis & diminish fungicidal mechanisms
- DKA: weak neutrophil, low pH, higher glucose level, free iron
- Mucorales is able to extract iron from desferrioxamine.

#### Isavuconazole:

- Broad spectrum 2<sup>nd</sup> gen. triazole
- Inhibit CYP enzyme laosterol 14-alpha-demethylase (CYP51) –blocking synthesis of ergosterol
- Metabolites via CYP3A4 & CYP3A5 which may alter the plasma concentrations
- a moderate inhibitor of CYP3A4, and a mild inhibitor of P-glycoprotein (P-gp), and organic cation transporter 2 (OCT2)

Table 1 In vitro activity of isavuconazole against clinically important species of Aspergillus and Mucorales (adapted from Ref. [15])

| Organism             | No. of isolates | MIC range <sup>a</sup> (μg/mL) | MIC <sub>90</sub> range <sup>a</sup> (μg/mL) | MFC range <sup>a</sup> (μg/mL) |
|----------------------|-----------------|--------------------------------|--|--------------------------------|
| Aspergillus species  |                 |                                | 1  |                                |
| A. flavus            | 97              | 0.25-16                        | 1–16   | 0.5-4                          |
| A. fumigatus         | 939             | 0.06-4                         | 0.5–2  | 0.125-4                        |
| A. nidulans          | 70              | 0.06-2                         | 1  | NA                             |
| A. niger             | 84              | 0.125 to >16                   | 2-4  | 0.25 to >8                     |
| A. terreus           | 222             | 0.125 to >16                   | 0.54   | 0.25-2                         |
| Mucorales            |                 |                                | c\\`0  |                                |
| Cunninghamella spp.  | 25              | 0.12 to >8                     | \$8/~  | 2 to >16                       |
| Lichtheimia spp.     | 111             | 0.03 to >8                     | 1 to >8                                      | 4 to >16                       |
| Mucor circinelloides | 16              | 2-8                            | <a>8</a>                                     | NA                             |
| Mucor spp.           | 107             | <0.015 to >8                   | 2 to >8                                      | 2 to >16                       |
| Rhizomucor spp.      | 38              | <0.015 to >8                   | >8   | 2 to >8                        |
| Rhizopus spp.        | 189             | 0.12 to >8                     | 1 to >8                                      | 1 to >16                       |
| Syncephalastrum spp. | 2               | 0.125-4                        | NA   | 1–16                           |

NA not available, MFC minimum fungicidal concentration, MIC minimum inhibitory concentration, MIC<sub>90</sub> MIC at which 90 % of isolates are inhibited

- Isavuconazole: good in vitro activity against Rhizopus & Rhizomucor
- However, its activity is limited for other Mucolares especially Mucor circinelloides
- Overall, MIC of Mucorales higher than Aspergillus group

a Across individual studies reviewed in Ref. [15]

 A 57 year-old Thai man with β-thalassemia disease was admitted (day 0) due to low grade fever and swelling Rt arm & forearm (deep and superficial soft tissue) with rapid progression lesions for −3 months.

History of planting in a swampy area before lesion occurred.

KOH & PAS & GMS : Non-septate hyphae

#### What?? and How should we do next ??

Yellow tissue covered with pus, measuring 6x11 cm.

• CTA: Rt upper extremity: Occluded distal Rt. Brachial artery above the bifurcation.

 Pythium insidiosum antibody by ELISA: Pos

Dx: Pythiosis

Tx: Debridement + oral terbinafine & itraconazole + Immunotherapy



After 1st debridement (+6 days)



After 2<sup>nd</sup> debridement (+15 days)




Before discharge (+24 days)

#### Human pythiosis: Pythium insidiosum (fungus-like organism)


Only one case reported in 2011 ..... An American soldier acquired traumatic wound infection by Pythium aphanidermatum in Afghanistan (Farmer A et al. J clin Microbiol, 2011)



Macroscopic: Mycelium like fungi, rapid growing, submerged, white to colorless colony, 35C, 24h




Microscopic: Sparsely rare septate hyphae



LPCB wet mouth

# **Recent Taxonomy**

Kingdom Straminipila Class Oomycetes Order Pythiales




#### Phylogenetic tree of P. insiodiosum based on

- ITS region (Schurko et al. Mycol Res, 2003)
- IGS region (Frank N et al. Mycologia, 2003)
- Cox 2 gene (Kammarnjessadakul et al., Med Mycol, 2011)
- Exo-1,3-beta glucanase (Ribeiro TC et al. Infection, Genetics and Evolution, 2017)



# **Recent Taxonomy & Epidemiology**

Kingdom Straminipila Class Oomycetes Order Pythiales



Kammarnjessadakul et al., Med Mycol, 2011


#### Phylogenetic tree of P. insiodiosum based on

- ITS region (Schurko et al. Mycol Res, 2003)
- IGS region (Frank N et al. Mycologia, 2003)
- Cox 2 gene (Kammarnjessadakul et al., Med Mycol, 2011)
- Exo-1,3-beta glucanase (Ribeiro TC et al. Infection, Genetics and Evolution, 2017)



## **Natural habitat**

- Tropical & Sub tropical regions
- Moist soil / stagnant water ie. rice field
- Also has been isolated from irrigation water and reservoir in northern part of Thailand (Supabandhu, Med Mycol, 2008)








Environmental form Hyphae&zoospore form Infected Stage **Zoospore form** 

Infected Host **Hyphae form** 

# **Clinical manifestations**

#### **Vascular pythiosis**






Orbital and Facial Infection

Kirzhner M, J Ped Inf Dis. 2014

#### Cerebral pythiosis (cerebral hemisphere)




# Keratitis pythiosis






#### (sub) Cutaneous form



# **Human Pythiosis**

- Human pythiosis was first described in Thailand, in 1987.
- So far Thailand has been ranged as the highest incidence of human pythiosis in the world.



 Base on the immunotherapy requested from Mycology unit, KCMH, the increasing trend was presented.

# **Human Pythiosis**

**Pubmed Search** (search on 29<sup>th</sup> Nov 2017)

|                             |             | Number of pul                      | blications |
|-----------------------------|-------------|------------------------------------|------------|
| Keywords                    | Before 2006 | 2006-present<br>(12 years approx.) | Total      |
| Human pythiosis             | 36          | 87                                 | 123        |
| Pythium in human            | 75          | 120                                | 195        |
| Human pythiosis case report | 10          | 22                                 | 32         |
| Human vascular pythiosis    | PLE 6       | 14                                 | 20         |
| Human keratitis pythiosis   | 6           | 10                                 | 16         |
| Human ocular pythiosis      | 2           | 12                                 | 14         |
| Thai human pythiosis        | 3           | 11                                 | 14         |



# **Human Pythiosis**

 Not only in Thailand, some human pythiosis cases were also reported from other country around the world except Europe.

| Regions   | Country                       | Pythiosis Cases  | Reference               |
|-----------|-------------------------------|--|-------------------------|
| Asia      | Malaysia<br>(Kuala Lumpur)    | Pythium keratitis disposable contact lens wear, and swimming in the Kelang River                     | Badenoch et al., 2001   |
|           | India<br>(Telangana)          | 13 Pythium keratitis cases during 2010-2012  | Sharma S et al. 2015    |
|           | China<br>(Hainan)             | Pythium keratitis in a boy who was scraped by twigs while climbing a tree                            | Hong H et al. 2016      |
|           | Israel                        | Contact lens-related Pythium keratitis   | Tanhehco TY et al. 2011 |
| Australia | New Zealand<br>(Auckland)     | Keratitis pythiosis in a man who played ball in hot pool   | D Murdoch et al. 1997   |
|           | Australia<br>(Darwin)         | Keratitis pythiosis in a child who swam in public and backyard swimming pools                        | Badenoch PR et al. 2009 |
|           | Australia                     | 2 cutaneous pythiosis cases with the history of exposure to either swampy water or horses.           | Triscott JA et al. 1993 |
| America   | Brazil                        | Subcutaneous pythiosis in a police after spend his vacation with water-associated leisure activities | Bosco M et al. 2005     |
|           | USA<br>(Iowa, Florida, Texas) | 5 Orbital pythiosis in young children  | Mendoza L et al. 2004   |


|                           | Vascular form   | Ocular form   |
|---------------------------|---|---|
| Symptoms                  | <ul> <li>Presents as granulomatous cutaneous and subcutaneous lesions</li> <li>Intermittent claudication</li> <li>Arterial obstruction / aneurysm resulting ischemia / gangrene</li> <li>Other signs of arterial insufficiency</li> </ul> | <ul> <li>pain and redness</li> <li>Less vision</li> <li>Ulcerative keratitis which may progress to endophthalmitis</li> </ul> |
| Underlying Dis. & History | <ul> <li>Underlying hemoglobinopathy (thalassemia, PNH)</li> <li>Agriculture-related occupations ie. farmer or history of water exposure</li> </ul>   | <ul><li>No</li><li>Water spilled</li></ul>  |

#### **Vascular form**


#### **Ocular form**

#### Diagnosis


 Arterial occlusion by CT angiogram Confocal microscope
 Beaded string-like with mean branching angles at 78.6 degrees.
 The diameter of the hyphae varied from 1.5 to 7.5 mm. (95% sens.)



Positive Arterial occlusion by CT angiogram




#### Vascular form **Ocular form Diagnosis** Arterial occlusion by angiogram P. insidiosum specific antibody (ID / ELISA / WB / Lateral flow / HA) P. insidiosum isolation & zoospore Positive for *P. insidiosum* isolation & production zoospore production Molecular approach for identification both Molecular approach for identification culture and specimens both culture and specimens Histopathology Histopathology Mittal et al., Basic Invest, 2017



PAS (5 mins); Pythium spp. >> 1+ to 2+ PAS (5 mins); Other fungal infection >> 4+

Cellulose: a weaker reaction than chitin and pectin, so it needs a longer exposure time to PAS for complete oxidation to aldehydes, which then reacts with Schiff reagent to give a magenta color (purplish-red).

# IKI-H<sub>2</sub>SO<sub>4</sub> staining



Mittal et al., Basic Invest, 2017



|           | Vascular form  | Ocular form                                |
|-----------|--|--|
| Treatment | AK amputation or debridement                                 | Corneal grafting or enucleation            |
|           | <ul> <li>Antifungal agent: Itraconazole + Terbina</li> </ul> | afine • Amphotericin B /terbinafine/Azoles |
|           | Immunotherapy by PIA   | Immunotherapy by PIA                       |
|           | PRESENTED AT MINITIAL CHILD AS OPHICAL ON                    |  |



J Antimicrob Chemother. 2015;70(6):1885-92. doi: 10.1093/jac/dkv008. Epub 2015 Jan 27.

Treatment outcomes of surgery, antifungal therapy and immunotherapy in ocular and vascular human pythiosis: a retrospective study of 18 patients.

Permpalung N<sup>1</sup>, Worasilchai N<sup>2</sup>, Plongla R<sup>3</sup>, Upala S<sup>4</sup>, Sanguankeo A<sup>4</sup>, Paitoonpong L<sup>3</sup>, Mendoza L<sup>5</sup>, Chindamporn A<sup>8</sup>.



## Retrospective study in 18 pythiosis cases in KCMH from 2003 to 2013

#### Vascular pythiosis; n=9

- 44% of vascular cases died
- Definitive surgery with adequate surgical margins

#### Ocular pythiosis; n=9

- 55% of ocular pythiosis underwent enucleation.
- Age might be one prognostic factor, significantly younger of non-enucleated cases than those who underwent enucleation.
- Higher non-enucleated cases (45%) was found in our center than others (12-21%), might have been due to the routine administration of PIA in our center.

Int J Low Extrem Wounds, 2015 Sep;14(3):245-50. doi: 10.1177/1534734615599652. Epub 2015 Aug 18.

Vascular Pythiosis of the Lower Extremity in Northern Thailand: Ten Years' Experience.

Reanpang T1, Orrapin S1, Orrapin S1, Arworn S1, Kattipatanapong T2, Srisuwan T2, Vanittanakom N3, Lekawanvijit SP4, Rerkasem K5.

# Retrospective study in 22 vascular cases: 10-years period (2004-2014) in Maharaj Nakorn Chiang Mai, Chiang Mai University Hospital.


- Successful management of vascular pythiosis requires early recognition
- 4 classic clinical presentations need to be concerned:
  - (1) underlying thalassemia
- (3) history of previous leg wound
- (2) no atherosclerotic risk
- (4) presentation with acute or chronic limb ischemia


# Important to note that "serum antibody for *Pythium* should be tested in all suspected cases before treatment"

- Survival rate was around 63.6%.
- The only effective treatment was complete excision of the infected tissue, which was done mainly by major amputation.
- This report raises awareness of this disease, which needs preemptive diagnosis and appropriate treatment.



# One more novel technology can help for pythiosis diagnosis





- Thermophillic helicase DNA Amplification (tHDA) using P. insidiosum specific primer
  - Isothermal DNA amplification, no need PCR machine
  - Rapid & accurate, species-specific identification
- Can differentiate P. insidiosum from closely related pathogenic fungi by CviKI-1 digestion.
- Limit of Detection :
  - o 100 pg (1.74 × 10<sup>2</sup> copies) for 1-step protocol
  - $^{\circ}$  100 fg (1.74 × 10<sup>-1</sup> copies) for 2-step protocol add denature step
- Directly amplification in clinical samples was also evaluated.




# One more novel technology....for clade pythiosis diagnosis

High Resolution Melting Analysis: A Novel Approach for Clade Differentiation in *Pythium insidiosum* and Pythiosis.

Navaporn Worasilchai, Nitipong Permpalung, Ariya Chindamporn

- Real-time polymerase chain reaction (qPCR) with subsequent High Resolution Melting (HRM) using P. insidiosum specific primer
  - No need sequencing step
  - Rapid & accurate, clade-specific identification
- Limit of Detection :
  - 100% specificity
  - 1 pg limit of detection

Worasilchai et al., Med Mycol, 2017



**HRM** 

Normalized graph (A) and difference graph (B): comparison among Clade  $A_{TH}$ , Clade  $B_{TH}$ , and  $C_{TH}$  *P. insidiosum* (—) and other related fungi (---) which were amplified *COX2* gene: *L. albertoi* (1); *P. aphanidermatum* (2); *P. catenulatum* (3); *C. coronatus* (4); *Phy. sojae* (5);

B. meristosporus (6); Phy. parasitica (7)

#### ...Take home messege...

#### **Mucormycosis**

- Underlying dis. in developed country: DM; developing country: HM
- Seems like a clear sky of treatment in future: 2<sup>nd</sup> triazole
- From translational research of pathogenesis ! CotH member -

## Guideline for pythiosis diagnosis (Thai patients, experience)

#### Vascular pythiosis

- Underlying hemoglobinopathy ie. thalassemia, PNH etc.
- Agricultural related occupations e. farmer or history of water exposure
- Present acute or chronic ischemia with rapid progression
- No atherosclerotic risk & no response to any antifungal agents

#### **Ocular pythiosis**

- History of water spilled to the eye
- Present ulcerative keratitis / endophthalmitis with rapid progression
- No response to any antifungal agents

